全文获取类型
收费全文 | 9840篇 |
免费 | 834篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 352篇 |
妇产科学 | 128篇 |
基础医学 | 1181篇 |
口腔科学 | 386篇 |
临床医学 | 1084篇 |
内科学 | 2294篇 |
皮肤病学 | 108篇 |
神经病学 | 645篇 |
特种医学 | 594篇 |
外科学 | 1253篇 |
综合类 | 139篇 |
一般理论 | 5篇 |
预防医学 | 971篇 |
眼科学 | 165篇 |
药学 | 798篇 |
1篇 | |
中国医学 | 15篇 |
肿瘤学 | 547篇 |
出版年
2022年 | 70篇 |
2021年 | 182篇 |
2020年 | 89篇 |
2019年 | 169篇 |
2018年 | 219篇 |
2017年 | 162篇 |
2016年 | 172篇 |
2015年 | 199篇 |
2014年 | 268篇 |
2013年 | 411篇 |
2012年 | 554篇 |
2011年 | 538篇 |
2010年 | 323篇 |
2009年 | 354篇 |
2008年 | 470篇 |
2007年 | 512篇 |
2006年 | 495篇 |
2005年 | 476篇 |
2004年 | 465篇 |
2003年 | 375篇 |
2002年 | 432篇 |
2001年 | 171篇 |
2000年 | 160篇 |
1999年 | 205篇 |
1998年 | 177篇 |
1997年 | 205篇 |
1996年 | 177篇 |
1995年 | 144篇 |
1994年 | 143篇 |
1993年 | 147篇 |
1992年 | 130篇 |
1991年 | 121篇 |
1990年 | 116篇 |
1989年 | 148篇 |
1988年 | 134篇 |
1987年 | 115篇 |
1986年 | 121篇 |
1985年 | 118篇 |
1984年 | 103篇 |
1983年 | 96篇 |
1982年 | 100篇 |
1981年 | 104篇 |
1980年 | 65篇 |
1979年 | 76篇 |
1978年 | 53篇 |
1977年 | 68篇 |
1976年 | 68篇 |
1975年 | 36篇 |
1974年 | 46篇 |
1972年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Individual and joint malingering detection accuracy of the Portland Digit Recognition Test (PDRT), Test of Memory Malingering (TOMM), and Word Memory Test (WMT) was examined in traumatic brain injury (TBI; 43 non-malingering, 27 malingering) and chronic pain (CP; 42 non-malingering, 58 malingering) using a known-groups design. At published cutoffs, the PDRT and TOMM were very specific but failed to detect about 50% of malingerers; the WMT was sensitive but prone to false positive errors. ROC analyses demonstrated comparable accuracy across all three tests. Joint classification accuracy was superior to that of the individual tests. Clinical and research implications are discussed. 相似文献
992.
993.
Sanders GD Al-Khatib SM Berliner E Bigger JT Buxton AE Califf RM Carlson M Curtis AB Curtis JP Domanski M Fain E Gersh BJ Gold MR Goldberger J Haghighi-Mood A Hammill SC Harder J Healey J Hlatky MA Hohnloser SH Lee KL Mark DB Mitchell B Phurrough S Prystowsky E Smith JM Stockbridge N Temple R;Expert panel participating in a Duke Center for the Prevention of Sudden Cardiac Death-sponsored conference 《American heart journal》2007,153(6):951-959
Although current evidence supporting a more precise strategy for identifying patients at highest risk for sudden cardiac death (SCD) is sparse, strategies for translating existing and future evidence into clinical practice and policy are needed today. A great many unanswered questions exist. Examples include the following: At what level of risk for SCD should we pursue further testing or therapy? How should clinical strategies ethically and economically balance alternative outcomes? How can we best translate optimal strategies into clinical practice so as to prevent tomorrow's SCDs? On July 20 and 21, 2006, a group of individuals with expertise in clinical cardiovascular medicine, biostatistics, economics, and health policy was joined by government (Food and Drug Administration; Centers for Medicare and Medicaid Services; National Heart, Lung, and Blood Institute; Agency for Healthcare Research and Quality), professional societies (Heart Rhythm Society), and industry to discuss strategies for risk assessment and prevention of SCD. The meeting was organized by the Duke Center for the Prevention of Sudden Cardiac Death and the Duke Clinical Research Institute. This article, the second of 2 documents, summarizes the policy discussions of that meeting, discusses an analytic framework for evaluating the risks and benefits associated with SCD prevention and risk stratification, and addresses the translation of SCD risk assessment strategies into practice and policy. 相似文献
994.
Fonarow GC Yancy CW Albert NM Curtis AB Stough WG Gheorghiade M Heywood JT Mehra M O'Connor CM Reynolds D Walsh MN 《American heart journal》2007,154(1):12-38
Evidence-based consensus treatment guidelines are available to assist physicians with the management of chronic heart failure (HF). Although it has been generally presumed that physicians incorporate these treatment guidelines into clinical practice, the actual assimilation of evidence-based strategies and guidelines has been demonstrated to be less than ideal. Studies of HF care show that treatment guidelines are slowly adopted and inconsistently applied and, thus, often fail to lead to improvements in patient care and outcomes. There are a number of ongoing, large, national quality improvement registries that are following the clinical care and outcomes of inpatient HF treatment. However, to date, there have been no similar quality improvement registries in the outpatient arena. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) is the first large, comprehensive performance improvement registry designed to characterize the current outpatient management of systolic HF and assess the effect of practice-specific process improvement interventions consisting of education, specific clinical guidelines, reminder systems, benchmarked quality reports, and structured academic detailing on the use of evidence-based HF therapies. Seven performance measures to quantify the quality of outpatient HF care were explicitly developed by the IMPROVE HF Steering Committee. The primary objective is to observe, over the aggregate of IMPROVE HF practice sites, a relative > or = 20% improvement in at least 2 of the 7 performance measures at 24 months, compared with baseline. Deidentified clinical data from the medical records of a planned 43,000 patients from 160 US cardiology practices will be included in this study. 相似文献
995.
Curtis JP Cohen DJ Jones PG Bach RG Spertus JA Krumholz HM 《The American journal of cardiology》2007,99(9):1227-1229
We used data from 1,344 patients enrolled in the Prospective Registry Evaluating Myocardial Infarction: Events and Recovery study to examine the adoption of drug-eluting stents (DESs) and the effect of the release of the Food and Drug Administration's preliminary public health notification, which raised concerns about DES safety. Overall, there was a dramatic increase in the use of DESs over the study period, from 32% in April 2003 to 81% in March 2004. The notification issued on October 29, 2003 was associated with a 26% relative decrease in DES use. By January 2004, DES use had returned to the prenotification rate and continued to increase thereafter. In conclusion, the Food and Drug Administration's notification had a modest but temporary effect on clinical practice. 相似文献
996.
J. Curtis Nickel Joe Downey Francois Bénard Michael Chetner John Grantmyre Alan So Paul Whelan 《Canadian Urological Association journal》2008,2(4):367-373
Objective
To determine the prevalence, diagnostic patterns and management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in Canadian urology outpatient practice.Methods
Representative urologists were randomly selected from lists provided by the Canadian and Quebec Urological Associations. Each patient identified with a BPH diagnosis during a typical 2-consecutive-week period during April, May or June 2007 was asked to complete a corresponding International Prostate Symptom Score (IPSS) questionnaire. Each day, the participant urologist completed an outpatient log and a detailed programmed chart review to transcribe demographics, investigations and treatments associated with each BPH patient.Results
Eighty-six urologists were invited to participate. Thirty-eight (44.2%) agreed, and 27 of those (71.1%) submitted evaluable data for the audit. Of the 5616 patients seen in outpatient practice (average 208 per urologist), 4324 (77%) were male. A BPH diagnosis was identified in 19.6% of the men (n = 849; mean age 69.5, standard deviation [SD] 10, yr; age range 40–100 yr; mean duration of symptoms 4.8, SD 4.2, yr; mean IPSS score 12.3, SD 7.4; mean prostate specific antigen [PSA] 3.9, SD 3.9, ng/mL). Twenty-four percent of patients had prostates that were rated as large, 50% as medium and 26% as small. PSA level correlated positively with prostate volume. Twenty-two percent were initial consultations for LUTS and 78% were repeat visits. Diagnostic evaluation tended to follow those examinations and tests recommended by the Canadian BPH guidelines. Treatment choices tended to follow an evidence-based algorithm with respect to treatment choices for men in the various prostate-volume and PSA groups.Conclusion
This prospective audit indicates that BPH remains a common condition managed by urologists in outpatient practice. Investigations and treatments confirm that Canadian urologists appear to be following Canadian BPH guidelines as well as the most recent evidence from the literature. 相似文献997.
J. Curtis Nickel Jack Barkin Caroline Koch Charles Dupont Mostafa Elhilali 《Canadian Urological Association journal》2008,2(1):16-21
Objective
Our Canadian multicentre open-label study sought to evaluate, in patients with moderate/severe lower urinary symptoms (LUTS) secondary to benign prostatic hyperplasia, the effect on symptoms of 9 months of monotherapy with finasteride 5 mg following 9 months of combination treatment (finasteride with an α-blocker) as quantified according to the International Prostate Symptom Score (IPSS).Methods
The primary outcome measure for efficacy was the maintenance of IPSS response after cessation of the α-blocker. Subjects were treated with a combination of finasteride and an α-blocker for 9 months and then with finasteride alone for 3 or 9 months.Results
Results showed that the IPSS scores after 3 months of monotherapy were within the criteria for equivalence to those after 9 months of combination therapy. Symptom control equivalence was also found after 9 months of monotherapy. The IPSS response rate was also similar for combination and monotherapy. The safety profile was similar and as expected with these medications.Conclusion
Control of LUTS associated with BPH thus appears to be maintained for at least 9 months with finasteride alone, following a 9-month course of combination therapy with finasteride and an α-blocker, with similar safety profiles. 相似文献998.
999.
Geisler JP Orr CJ Manahan KJ 《Journal of laparoendoscopic & advanced surgical techniques. Part A》2008,18(5):727-729
Adenosarcomas are rare cervical tumors with unknown optimal treatment, which often affects young women. A 23-year-old woman was found to have a stage IB1 adenosarcoma of the cervix. She underwent a robotically assisted total laparoscopic radical trachelectomy with the placement of abdominal cerclage for the sparing of fertility. 相似文献
1000.
Mikhail P Hess PJ Klodell CT Beaver TM Lee A Tribble CG Martin TD 《The Annals of thoracic surgery》2008,85(2):e9-11
Type I endoleaks occasionally persist after endovascular repair of thoracic aneurysms. A technique for repair is described using dimensions obtained from preoperative imaging, in which the aorta is banded at the endograft attachment zone. Aortic remodeling and aortic dimensional stability are the mainstays of the approach. Measured banding has also proved to be useful for the preparation of a landing zone prior to endograft placement during hybrid procedures. 相似文献